We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.
- Authors
Yusuke Okuma; Yukio Hosomi; Shingo Miyamoto; Masahiko Shibuya; Tatsuru Okamura; Tsunekazu Hishima; Okuma, Yusuke; Hosomi, Yukio; Miyamoto, Shingo; Shibuya, Masahiko; Okamura, Tatsuru; Hishima, Tsunekazu
- Abstract
<bold>Background: </bold>Thymic carcinoma is a rare cancer with minimal evidence of a survival benefit following chemotherapy. An oral fluoropyrimidine of S-1, however, is the recommended active cytotoxic chemotherapy agent for refractory thymic carcinoma based on a case series, whereas sunitinib or everolimus are recommended as molecular-targeted agents based on Phase II trials. We retrospectively investigated the efficacy of S-1 for refractory thymic carcinoma and performed a biomarker analysis.<bold>Methods: </bold>We assessed the clinicopathological variables of 14 consecutive patients who underwent S-1 for refractory thymic carcinoma and correlated the clinical outcomes with potential biomarkers using paraffin-embedded cancer tissues of eight patients in the cohort.<bold>Results: </bold>A total of 178 thymic malignancies were identified, of whom 14 patients included 12 cases of squamous cell carcinoma, one lymphoepithelioma-like carcinoma, and one undifferentiated carcinoma. Six patients exhibited a partial response (42.9 %: 95 % confidence interval [CI], 21.4-67.4) and the disease control rate was 85.7 % (60.0-96.0 %). After a median follow-up of 24.2 months, the median progression-free survival was 8.1 months (range, 2.6-12.2 months), and median overall survival was 30.0 months (range, 6.2-41.9 months). No significant correlation between biomarker expression and response was noted. However, thymidine synthase (TS)/dihydropyrimidine dehydrogenase and TS/orotate phosphoribosyltransferase were observed.<bold>Conclusions: </bold>S-1 for refractory thymic carcinoma offered clinical activity and achieved an 85 % disease control rate. Although the biomarkers did not correlate with clinical outcome, the study results showed efficacy of S-1 as a cytotoxic chemotherapy for refractory thymic carcinoma, which warrants future investigation.
- Subjects
THYMUS cancer; BIOMARKERS; CANCER chemotherapy; DIHYDROPYRIMIDINE dehydrogenase; SQUAMOUS cell carcinoma; ANTINEOPLASTIC agents; FLUOROURACIL; RNA metabolism; HETEROCYCLIC compounds; THERAPEUTIC use of antimetabolites; COMBINATION drug therapy; COMPARATIVE studies; DRUG resistance in cancer cells; GENE expression; RESEARCH methodology; MEDICAL cooperation; METASTASIS; RESEARCH; RNA; TUMOR classification; THYMUS tumors; DISEASE relapse; EVALUATION research; TREATMENT effectiveness; RETROSPECTIVE studies; DISEASE progression; DIAGNOSIS
- Publication
BMC Cancer, 2016, Vol 16, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-016-2159-7